According to the latest market research study released by Technavio, the global neurological biomarkers market is expected to grow at a CAGR of over 15% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global neurological biomarkers market based on product type:
Global neurological biomarkers market by product type 2015
|
Genomics |
44.1% |
|
Proteomics |
33.8% |
|
Metabolomics |
17.6% |
|
Imaging |
4.5% |
Source: Technavio
Genomics-based biomarkers
The genomic-based biomarker dominated the market and accounted for around 44% of the total market share in 2015. Quality-based biomarkers are mostly used for screening, demonstrative, and prognostic tests. The genomic markers are still evolving, and recent developments and technically innovations will propel the growth of the market during the forecast period. Some of the progress in the market include high-throughput sequencing, single-nucleotide polymorphism (SNP) chips, and multiplexed and various quality neurological biomarker measures. The most widely used genomic markers are SNP chips, copy number variation (CNV), transformations, and epigenetic deviations.
“The improvements in cutting-edge sequencing for innovation and low expenses help in the utilization of genome sequencing for discovery and examination of neurological biomarkers. The usage of quality biomarkers like Pharmacogenomics can recognize the risks associated with the treatment with specific medications of neurological disorders more efficiently,” says Srinivas Sashidhar, a lead analyst at Technavio for research on orthopedics and general medical devices.
Proteomics-based biomarkers
The proteomics-based biomarker occupied almost 34% of the total market share in 2015. The low-availability proteins have led to the discovery of various clinically essential protein biomarkers to cure neurological diseases. The testing of human samples like serum, salivation, urine, and other body fluids to identify neurological biomarkers aid in the improvement of non-invasive tests for repeated studies. Advancements in proteomic profiling based on mass spectra will help in the discovery of biomarkers. Multiplexed protein biomarker assays have future for better symptomatic and prognostic value. The protein biomarkers are progressively examining and working towards drug discovery for neurological diseases. Testing methods have led to recognizable proof of biomarkers for developing a target-specific medication, approval, and use as companion diagnostics.
Metabolomics-based biomarkers
The proteomics-based biomarker occupied almost 18% of the total market share in 2015. This methodology is extensive used for oncology and other complex sicknesses that require non-invasive, real-time diagnosis, and monitoring. It is mainly used as a prognostic tool and samples analyzer in the disease screening process. It can also be used for pharmaceutical, biotechnological drug development and disease categorization and prognosis. Metabolomics have the technical advantage of translatability of information and models between species. The advancements in analytical methods and metabolomics assay kits have resulted in the increased adoption of these biomarkers in pharmaceutical and biological research areas. The developments in ionization electrospray-mass spectrometry (IMS-MS) or liquid chromatography-ionization micro spray mass spectrometry (LC-IMS-MS) will continue during the forecast period.
Imaging-based biomarkers
The imaging-based biomarker occupied around 5% of the total market share in 2015. The developments in Fourier transform infrared (FTIR) as the essential analytical tool is used for the diagnosis of cancer and neurological diseases. This tool has a unique feature to provide faster micro-scale that helps in determining the macromolecular chemical structure. The utilization of invasive techniques ensures accurate diagnosis and conclusion. There is constant development in areas like discovery/validation, assay development, and testing in the imaging-based biomarker segment. The application of FTIR imaging in Alzheimer’s studies has the ability to give cellular and sub-cellular chemical images.
The top leading vendors operating in the global neurological biomarkers market are:
- QIAGEN
- Myriad RBM
- Proteome Sciences
- Thermo Fisher Scientific
Other prominent vendors in the market include AbaStar MDx, Abiant, Acumen Pharmaceuticals, Aepodia, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, Cisbio Bioassays, Diagenic, Proteosys, and Psynova Neurotech.
A more detailed analysis is available in the Technavio report titled, ‘Global Neurological Biomarkers Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Biobanking Market 2016-2020
- Global Central Nervous System Disorders Therapeutics Market 2016-2020
- Global Neurophysiology Needles and Electrodes Market 2016-2020
- Neurodiagnostic and Monitoring Devices Market in the US 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
